New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.

TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.

Your daily dose of the clinical news you may have missed.

New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.

Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.

Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.

TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.

TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.